Learn about Merck’s research into immuno-oncology medicines that harness the patient’s immune system to fight cancer, including targeting programmed death-ligand 1 (PD-L1)
Learn about Merck’s research into immuno-oncology medicines that harness the patient’s immune system to fight cancer, including targeting T-cell immunoglobulin and ITIM domain (TIGIT)
Learn about Merck’s research into the monoclonal antibody, cetuximab, that induces tumor cell death by blocking the epidermal growth factor receptor (EGFR) and disrupting
EGFR signaling
Log in to the STARTone Portal for information on investigator-sponsored studies and grants to support Independent Medical Education (IME) and Continuing Medical Education (CME), Fellowships and Treatment Guidelines
5 Min
GL-MULO-00232 | December 2025
Welcome to Merck Healthcare!
Help us direct you to the right information by selecting one of the following options: